# Correction to: Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma

PMC · DOI: 10.1093/oncolo/oyag031 · The Oncologist · 2026-02-17

## Full-text entities

- **Diseases:** urothelial carcinoma (MESH:D014523)
- **Chemicals:** pembrolizumab (MESH:C582435), enfortumab vedotin (MESH:C000632577)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12923106/full.md

---
Source: https://tomesphere.com/paper/PMC12923106